Galectin Therapeutics, Inc. (GALT)
3.29
-0.09
(-2.66%)
USD |
NASDAQ |
Nov 11, 16:00
3.31
+0.02
(+0.61%)
After-Hours: 20:00
Galectin Therapeutics Enterprise Value : 344.86M for Nov. 11, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 11, 2026 | 344.86M |
| November 10, 2026 | 350.83M |
| November 09, 2026 | 356.13M |
| November 06, 2026 | 334.91M |
| November 05, 2026 | 324.64M |
| November 04, 2026 | 356.80M |
| November 03, 2026 | 348.84M |
| November 02, 2026 | 347.51M |
| October 30, 2026 | 346.85M |
| October 29, 2026 | 360.11M |
| October 28, 2026 | 361.44M |
| October 27, 2026 | 350.83M |
| October 26, 2026 | 338.23M |
| October 23, 2026 | 338.23M |
| October 22, 2026 | 350.83M |
| October 21, 2026 | 350.17M |
| October 20, 2026 | 354.14M |
| October 19, 2026 | 358.46M |
| October 16, 2026 | 366.74M |
| October 15, 2026 | 372.71M |
| October 14, 2026 | 368.07M |
| October 13, 2026 | 371.39M |
| October 12, 2026 | 383.32M |
| October 09, 2026 | 387.96M |
| October 08, 2026 | 368.07M |
| Date | Value |
|---|---|
| October 07, 2026 | 366.74M |
| October 06, 2026 | 376.03M |
| October 05, 2026 | 374.04M |
| October 02, 2026 | 385.31M |
| October 01, 2026 | 376.03M |
| September 30, 2026 | 383.99M |
| September 29, 2026 | 385.97M |
| September 28, 2026 | 387.30M |
| September 25, 2026 | 385.31M |
| September 24, 2026 | 389.29M |
| September 23, 2026 | 395.26M |
| September 22, 2026 | 401.23M |
| September 21, 2026 | 389.29M |
| September 18, 2026 | 384.65M |
| September 17, 2026 | 372.71M |
| September 16, 2026 | 370.72M |
| September 15, 2026 | 374.04M |
| September 14, 2026 | 381.33M |
| September 11, 2026 | 385.97M |
| September 10, 2026 | 385.31M |
| September 09, 2026 | 395.26M |
| September 08, 2026 | 401.23M |
| September 04, 2026 | 432.39M |
| September 03, 2026 | 415.15M |
| September 02, 2026 | 423.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Mirum Pharmaceuticals, Inc. | 6.539B |
| ACADIA Pharmaceuticals, Inc. | 2.270B |
| Alnylam Pharmaceuticals, Inc. | 20.81B |
| Anika Therapeutics, Inc. | 168.04M |
| Savara, Inc. | 926.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.113M |
| Total Expenses (Quarterly) | 9.113M |
| EPS Diluted (Quarterly) | -0.1393 |
| Earnings Yield | -13.06% |
| Normalized Earnings Yield | -11.56 |